The estimated Net Worth of Bruce Greenberg is at least $879 mil dollars as of 12 August 2024. Mr Greenberg owns over 10,834 units of Aldeyra Therapeutics Inc stock worth over $782,305 and over the last 2 years he sold ALDX stock worth over $96,369.
Mr has made over 2 trades of the Aldeyra Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 10,834 units of ALDX stock worth $51,353 on 12 August 2024.
The largest trade he's ever made was selling 13,201 units of Aldeyra Therapeutics Inc stock on 9 March 2024 worth over $45,015. On average, Mr trades about 6,009 units every 39 days since 2022. As of 12 August 2024 he still owns at least 126,382 units of Aldeyra Therapeutics Inc stock.
You can see the complete history of Mr Greenberg stock trades at the bottom of the page.
Bruce Greenberg CPA, M.B.A. is the VP & Controller at Aldeyra Therapeutics Inc.
Bruce's mailing address filed with the SEC is C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON, MA, 02421.
Over the last 10 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson..., eAdvisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include: